THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

GLIOMATCH selected for Horizon Europe funding

The GLIOMATCH project aimed at advancing precision medicine for brain cancer patients has received a total funding of €12.59 million from the EU, Switzerland, and the UK.

GLIOMATCH is now a Horizon Europe funded Research and Innovation Action. The project is aimed at improving the outcome of malignant brain tumours in adults and children, as well as better understanding immunotherapy for brain cancer treatment.

By investigating solutions to alleviate the societal impacts of brain cancer, the project aligns with the objectives of the EU Cancer Mission and contributes to the United Nations’ Sustainable Development Goals 2 and 4.

It is a five year project starting in January 2024 and aligning 14 pan-European partners from 10 different member states.

More Posts

GLIOMATCH results contribute to new EIC-funded project GLIOBREAK

Results from GLIOMATCH are supporting the newly funded EIC Transition project GLIOBREAK, coordinated by Beactica Therapeutics and with the involvement of KU Leuven. The project will advance BEA-17, a first-in-class LSD1–CoREST degrader, towards clinical readiness, including IND-enabling studies and regulatory submission.

International Childhood Cancer Day 2026

On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.

International Day of Women and Girls in Science 2026

GLIOMATCH celebrates the women researchers across its consortium whose expertise and commitment drive the development of tailored immunotherapies for malignant brain tumours, marking the International Day of Women and Girls in Science 2026.